Exhibit 10.17

HemoBioTech[Graphic Omitted]

2110 Research Row
Suite 457
Dallas, Texas 75235
469-585-7613
972-620-9830 fax
arthurb@flash.net




July 13, 2005



Dr. Jan Simoni
Department of Surgery
Texas Tech Health Science Center
3601 4th Street
Stop 8312
Laboratory 3A136
Lubbock, Texas 79420

Dear Dr. Simoni:

This will confirm the agreement  between you and  Hemobiotech,  Inc., a Delaware
corporation  ("HBT"),  with respect to your providing  advisory services to HBT.
Set forth below are the terms and conditions mutually agreed upon:

1.    TERMS: This agreement shall be effective on the date of your acceptance of
      this letter as indicated  below and shall  continue  until  terminated  by
      either party upon 60 days written notice to the other, or until superseded
      by another agreement between parties.

2.    DUTIES:  As an advisor,  you are to provide HBT with advisory  services on
      technical,  medical and market issues related to HBT, including its second
      generation blood substitute, HemoTech.

3.    TIME AND COMPENSATION:  You shall make yourself  available for services by
      telephone  calls,  as well as at least one meeting every other month which
      can be implemented by telephone calls, one annual meeting at the company's
      facility plus additional  meetings if your schedule permits.  Upon signing
      this  agreement  you will receive  nonqualified  stock options to purchase
      271,528  shares of Common  Stock of HBT at an exercise  price per share of
      $0.18.  Fifty percent of the options shall become  exercisable on the date
      of the option grant,  25% will become  exercisable one year after the date
      of the option grant and the remaining options will become exercisable in a
      series of 36 successive equal monthly installments upon your completion of
      each additional  month of service as an advisor or other capacity with the
      company over the 36 month period  measured  from the one-year  anniversary
      date of the option grant. The options will be issued pursuant, and subject
      to, the terms of the Hemobiotech 2003 Stock Option/Stock Issuance Plan and
      the Non


                                       1



HemoBioTech[Graphic Omitted]



      Qualified Stock Option Agreement,  which will be provided separately.  All
      reasonable  expenses  incurred by you during the course of your service as
      an advisory  board  member  will be reimbursed by HBT within 45 days after
      submission by you of appropriate receipts documenting such expenses.

4.    CONFIDENTIALLY  AND  INVENTIONS:  Confidentially  and  Inventions  will be
      covered by the provisions in the License  Agreement dated January 22, 2002
      and the Sponsored  Research  Agreement (SRA) dated July 18, 2002 including
      the Phase 2 SRA dated  December 1, 2004,  between  Hemobiotech,  Inc., and
      Texas Tech University.


5.    This agreement  represents the entire  agreement  between the parties with
      respect to its subject matter.

If the foregoing represents your understanding of the agreement, please sign and
return the enclosed copy of this letter.


Best Regards,

Hemobiotech, Inc.

By: /s/ Arthur P. Bollon
    ---------------------------
    Arthur P. Bollon, Ph.D.
    Chairman and CEO




Accepted and Agreed:


By: /s/ Jan Simoni
    ---------------------------
    Jan Simoni, DVM, Ph.D.




                                       2